VEGF Inhibitor-Induced Hypertension Module

Toxicology Pharmacology Oncology Module vegf_inhibitor_hypertension 1 disorder Pathograph 8

A conserved treatment-toxicity module representing the final common pathway by which inhibition of vascular endothelial growth factor (VEGF) signalling raises systemic blood pressure. The culprit agent varies — the anti-VEGF antibody bevacizumab, the VEGFR2 antibody ramucirumab, the VEGF trap aflibercept, and the VEGF signalling pathway (VSP) tyrosine kinase inhibitors sunitinib, sorafenib, axitinib, pazopanib, cediranib, lenvatinib, cabozantinib and anlotinib — but because every one of them removes the same tonic VEGFA-VEGFR2 drive from the vascular endothelium, the downstream sequence repeatedly converges on loss of endothelial nitric oxide with oxidative stress, activation of the endothelin-1 system, microvascular rarefaction, vasoconstriction with a rise in peripheral vascular resistance, and treatment-emergent hypertension. This is a "side effect as mechanism" module in the same family as drug_induced_liver_injury, drug_induced_nephrotoxicity, myelosuppression and drug_hypersensitivity_scar: it captures adverse-drug-reaction pathophysiology shared across culprit drugs so that a drug-toxicity or cancer entry can declare conformance rather than re-deriving the chain. Deliberately scoped to the on-target antiangiogenic route to hypertension; other oncology routes to a raised blood pressure (proteasome inhibitors, corticosteroids, calcineurin inhibitors, androgen-deprivation therapy, and the hypertension of the underlying cancer or of renal impairment) are noted in the literature but are mechanistically distinct arms and are not modelled here.

⚙

Pathophysiology Nodes

6 shared nodes are defined in this module.

◉

Cell Types

⇄

Biological Processes

vascular endothelial growth factor receptor signaling pathway GO:0048010 DECREASED nitric oxide biosynthetic process GO:0006809 DECREASED response to oxidative stress GO:0006979 INCREASED endothelin receptor signaling pathway GO:0086100 INCREASED angiogenesis GO:0001525 DECREASED vasoconstriction GO:0042310 INCREASED blood vessel diameter maintenance GO:0097746 DECREASED regulation of blood pressure GO:0008217 ABNORMAL

Notes

This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g. "vegf_inhibitor_hypertension#Vasoconstriction and Increased Peripheral Vascular Resistance"). Conforming nodes should substitute the drug-specific route to VEGF pathway blockade — ligand sequestration (bevacizumab, aflibercept), receptor-antibody blockade (ramucirumab), or intracellular VEGFR2 kinase inhibition (the VSP tyrosine kinase inhibitors) — while preserving the conserved pathway-inhibition -> endothelial NO deficit / endothelin-1 activation / rarefaction -> vasoconstriction and raised resistance -> hypertension chain. The key conformance / central-effector target is "vegf_inhibitor_hypertension#Vasoconstriction and Increased Peripheral Vascular Resistance". Two framing guardrails curators must preserve. (1) The mechanism is NOT settled: the AHA scientific statement calls the exact molecular mechanisms unclear and the vascular-toxicity literature calls them elusive, so the three arms below are curated as complementary contributors rather than as one proven sequence — see the KNOWLEDGE_GAP discussion. (2) The toxicity is on-target, so raised blood pressure on a VSP inhibitor is reported as a candidate pharmacodynamic biomarker of antitumour efficacy; that association is recorded as an OPEN_QUESTION and must not be curated as an established prognostic claim. Related modules: tumor_angiogenesis models the VEGF axis as a cancer hallmark and is the therapeutic rationale this toxicity is the price of; drug_induced_nephrotoxicity covers the separate renal arm (proteinuria, thrombotic microangiopathy) of VEGF inhibition.

Discussions and Knowledge Gaps

Which of the three curated arms — endothelial nitric oxide deficiency with oxidative stress, endothelin-1 system activation, and microvascular rarefaction — is rate-limiting for the blood-pressure rise in patients, and in what temporal order do they act?

KNOWLEDGE GAP OPEN vegfi_hypertension_mechanism_unsettled

Attached to: Endothelial Nitric Oxide Deficiency and Oxidative Stress Endothelin-1 System Activation Microvascular Rarefaction Vasoconstriction and Increased Peripheral Vascular Resistance

This matters for curation discipline, not just completeness. The three upstream arms are each independently attested, but the field explicitly describes the integrated mechanism as unclear/elusive, so a conforming disorder entry must not assert one arm as "the" mechanism of its drug's hypertension. It also matters therapeutically: if endothelin-1 dominates, an endothelin receptor antagonist would be mechanism-matched therapy, whereas the two agents curated in this module's treatments block are chosen for convergence-node effect rather than for arm-specific targeting. The acute (tone) and slow (rarefaction) components also predict different blood-pressure time courses, which is testable.

Is treatment-emergent hypertension a usable pharmacodynamic biomarker of antitumour efficacy for VEGF pathway inhibitors, and if so does it warrant dose titration to a blood-pressure target?

OPEN QUESTION OPEN vegfi_hypertension_as_efficacy_biomarker

Attached to: Treatment-Emergent Hypertension

Because the toxicity is on-target, a rise in blood pressure plausibly indexes the degree of VEGF pathway inhibition actually achieved in a given patient, and a growing literature associates it with better cancer outcomes. The curation risk is real in both directions: recording the association as established would license a dangerous clinical inference (tolerate or induce hypertension to improve response), while omitting it hides the main reason this toxicity is studied. Curated here as open, with the reported limitation that the supporting data are constrained by study number and by incomplete understanding of the mechanism.

Should management of VEGF-inhibitor-induced hypertension continue to follow general-population hypertension guidelines, or does the distinct mechanism and the risk of rebound hypotension after cancer-therapy withdrawal require oncology-specific targets and agent choices?

OPEN QUESTION OPEN vegfi_hypertension_management_evidence_gap

Attached to: Treatment-Emergent Hypertension

The module's treatments block records angiotensin system inhibitors and calcium channel blockers as first-line, but that recommendation is extrapolated from general hypertension guidelines rather than derived from trials in this population — and the extrapolation is not obviously safe, because blood pressure falls again when the culprit drug is stopped. This is the practical knowledge gap the seed review for this module (PMID:42405920) was written to highlight.

↗

Used By Disorder Entries

Secondary Hypertension via VEGF Pathway Inhibitor Exposure → VEGF Signaling Pathway Inhibition , Drug-Induced Vasoconstriction and Increased Peripheral Vascular Resistance → Vasoconstriction and Increased Peripheral Vascular Resistance

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.

⚙

Pathophysiology

VEGF Signaling Pathway Inhibition

trigger

The conserved initiating lesion is pharmacological removal of tonic VEGFA-VEGFR2 signalling from the vascular endothelium. The route varies by agent — ligand sequestration by an anti-VEGF antibody or VEGF trap, receptor blockade by an anti-VEGFR2 antibody, or intracellular inhibition of the VEGFR2 kinase by a small-molecule tyrosine kinase inhibitor — but each silences the same receptor. Hypertension is the most common vascular toxicity of this drug class and is dose dependent, consistent with an on-target class effect rather than an idiosyncratic reaction.

vascular endothelial cell CL:0000115

vascular endothelial growth factor receptor signaling pathway GO:0048010 DECREASED

Used by disorders

Secondary Hypertension as VEGF Pathway Inhibitor Exposure

Downstream

Endothelial Nitric Oxide Deficiency and Oxidative Stress Loss of VEGFR2 drive withdraws the PI3K/Akt-eNOS stimulus that maintains endothelial nitric oxide production.
Endothelin-1 System Activation VEGF pathway blockade is accompanied by increased endothelin production and activation of the endothelin system.
Microvascular Rarefaction Withdrawal of the VEGF survival/angiogenic signal reduces microvessel density in peripheral vascular beds.

Endothelial Nitric Oxide Deficiency and Oxidative Stress

amplifier

VEGFR2 signalling normally sustains endothelial nitric oxide synthase activity through PI3K/Akt and MAPK, so pathway blockade lowers endothelial nitric oxide production. The resulting loss of the dominant endothelium-derived vasodilator is compounded by oxidative stress, which further consumes available nitric oxide. This is the best-characterised of the module's three parallel amplifier arms.

vascular endothelial cell CL:0000115

nitric oxide biosynthetic process GO:0006809 DECREASED response to oxidative stress GO:0006979 INCREASED

Downstream

Vasoconstriction and Increased Peripheral Vascular Resistance Loss of nitric-oxide-mediated vasodilator tone shifts the vessel wall toward constriction and raises resistance.

Endothelin-1 System Activation

amplifier

VEGF pathway blockade is accompanied by increased endothelin production and activation of the endothelin system. Endothelin-1 acting on smooth-muscle endothelin receptors is a potent vasoconstrictor, so this arm pushes the vessel wall toward constriction from the opposite direction to the nitric oxide deficit — a loss of vasodilator tone paired with a gain of vasoconstrictor tone.

vascular endothelial cell CL:0000115 vascular smooth muscle cell CL:0000359

endothelin receptor signaling pathway GO:0086100 INCREASED

Downstream

Vasoconstriction and Increased Peripheral Vascular Resistance Endothelin-1 acting on vascular smooth muscle is a direct vasoconstrictor stimulus.

Microvascular Rarefaction

effector

VEGF is a survival and maintenance signal for the microvasculature, so sustained pathway blockade reduces the density of functional capillaries and small vessels in peripheral beds. Rarefaction raises resistance structurally rather than by acute tone, which is consistent with the slower, sustained component of the blood-pressure rise and with its reversal after drug withdrawal.

vascular endothelial cell CL:0000115

angiogenesis GO:0001525 DECREASED

Downstream

Vasoconstriction and Increased Peripheral Vascular Resistance Loss of parallel microvascular conduits raises total peripheral resistance independently of vasomotor tone.

Vasoconstriction and Increased Peripheral Vascular Resistance

central effector

The three upstream arms — nitric oxide deficiency with oxidative stress, endothelin-1 system activation, and microvascular rarefaction — converge on a net shift of the peripheral circulation toward constriction and a rise in total peripheral vascular resistance. This is the central effector lesion and the key conformance target; conforming disorder nodes substitute the drug-specific route to VEGF blockade upstream but funnel through this step.

vascular smooth muscle cell CL:0000359 vascular endothelial cell CL:0000115

vasoconstriction GO:0042310 INCREASED blood vessel diameter maintenance GO:0097746 DECREASED

Used by disorders

Secondary Hypertension as Drug-Induced Vasoconstriction and Increased Peripheral Vascular Resistance

Downstream

Treatment-Emergent Hypertension Sustained elevation of peripheral vascular resistance raises systemic arterial blood pressure.

Treatment-Emergent Hypertension

consequence

The defining clinical consequence: a new or worsened elevation of systemic arterial blood pressure emerging on therapy. It is frequently dose limiting, it increases cardiovascular mortality in cancer survivors, and it is usually reversible after interruption or discontinuation of the culprit drug — the reversibility being a strong argument that the mechanism is on-target pharmacology rather than structural vascular damage.

regulation of blood pressure GO:0008217 ABNORMAL